Loading... Please wait... Loading... Please wait...
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
Axcella Health Inc. operates as a clinical stage biotechnology company in the United States. The company treats complex diseases and enhances health using endogenous metabolic modulator compositions. Its lead product candidates include AXA1665, which is in Phase 2 clinical trial for the reduction in risk of overt hepatic encephalopathy recurrence; and AXA1125 that is in Phase 2b clinical trial for treating non-alcoholic steatohepatitis, as well as in Phase 2a clinical trial for Long COVID therapy for patients. The company was formerly known as Newco LS16, Inc. and changed its name to Axcella Health Inc. in June 2016. Axcella Health Inc. was incorporated in 2008 and is based in Cambridge, Massachusetts.
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
Pharma stocks and the biotech sector can offer explosive gains. It also offers incredibly crushing defeats in which share prices decline precipitously....
The biotech sector never fails to offer up stocks full of massive issues at any given time. Developing novel therapeutic devices and pharmaceuticals is, after all, very expensive....
Here is how Axcella Health Inc. (AXLA) and Clover Health Investments, Corp. (CLOV) have performed compared to their sector so far this year....
Axcella Health (NASDAQ: AXLA ) stock is taking a beating on Friday after the biotechnology company announced plans for a reverse stock split. According to Axcella Health, shares of AXLA stock are goi...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company focused on pioneering a new approach to address the biology of complex diseases using com...
Axcella Health (NASDAQ: AXLA ) stock is falling on Thursday following its announcement of a new Covid-19 treatment patent. However, it's not that this is bad news for the clinical-stage biotechnology...
Axcella (AXLA) shares surge 299% after the company secures a methods-of-use patent for its lead candidate, AXA1125, which is currently under development to treat fatigue associated with Long Covid....
A little-known penny stock is among the market's top movers today. Axcella Health (NASDAQ: AXLA ) stock surged by as much as 280% on news that it has been granted an important new patent....
Axcella Health Inc (NASDAQ:AXLA) saw its stock rocket some 240% higher in Tuesday's early deals after the small-cap firm announced it had secured a patent for its treatment for ‘long' Covid fatigue....
